Barinthus Biotherapeutics plc
BRNS
$0.839
$0.0161.94%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -153.14% | 52.08% | -9.31% | 10.43% | -22.89% |
| Total Depreciation and Amortization | -6.96% | 1.20% | 5.87% | -0.79% | -5.79% |
| Total Amortization of Deferred Charges | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Non-Cash Items | 356.63% | 86.46% | 110.29% | -86.66% | 204.19% |
| Change in Net Operating Assets | 199.08% | -1,150.27% | 13.31% | 111.81% | -231.79% |
| Cash from Operations | 171.91% | -51.57% | -1.56% | 39.69% | -75.17% |
| Capital Expenditure | -143.86% | 40.63% | 37.66% | -301.31% | 525.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -143.86% | 40.63% | 37.66% | -301.31% | 525.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 80.00% | 29.89% | -28.83% | 361.47% | 136.96% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 80.00% | 29.89% | -28.83% | 361.47% | 136.96% |
| Foreign Exchange rate Adjustments | -218.98% | 1,829.69% | 27.44% | -143.85% | 172.86% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 153.96% | 4.30% | -0.64% | 33.48% | -43.22% |